1
|
Medwid S, Wigle TJ, Ross C, Kim RB. Genetic Variation in miR-27a Is Associated with Fluoropyrimidine-Associated Toxicity in Patients with Dihydropyrimidine Dehydrogenase Variants after Genotype-Guided Dose Reduction. Int J Mol Sci 2023; 24:13284. [PMID: 37686089 PMCID: PMC10487873 DOI: 10.3390/ijms241713284] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2023] [Revised: 08/21/2023] [Accepted: 08/24/2023] [Indexed: 09/10/2023] Open
Abstract
Dihydropyrimidine dehydrogenase (DPYD) is the rate-limiting enzyme involved in the metabolism of fluoropyrimidine-based chemotherapy. However, single-nucleotide variants (SNVs) in DPYD only partially explain fluoropyrimidine-induced toxicity. The expression of DPYD has previously been shown to be regulated by microRNA-27a (miR-27a) and a common miR-27a SNV (rs895819) has been associated with an increased risk of toxicity in patients harboring a DPYD variant who received standard fluoropyrimidine dosing. We investigated if the miR-27a rs895819 SNV was associated with toxicity in DPYD wildtype patients and carriers of DPYD variants who received a reduced dose. The regulation of DPYD using miR-27a was investigated in HepG2 cells utilizing a miR-27a mimic. miR-27a overexpression decreased DPYD mRNA expression compared to control cells (p < 0.0001). In a cohort of patients that received pre-emptive DPYD genotyping, 45 patients had a DPYD variant and 180 were wildtype. Patients heterozygous for rs895819 had an increased risk of toxicity, which was seen in both patients who were wildtype for DPYD variants (OR (95%CI) = 1.99 (1.00-3.99)) and DPYD variant carriers (OR (95%CI) = 8.10 (1.16-86.21)). Therefore, miR-27a rs895819 may be a clinically relevant predictor of fluoropyrimidine-associated toxicities. Furthermore, toxicity was more profound in DPYD variant carriers, even after DPYD genotype-guided dose reduction. This suggests that patients may benefit from miR-27a genotyping to guide fluoropyrimidine dosing.
Collapse
Affiliation(s)
- Samantha Medwid
- Department of Medicine, University of Western Ontario, London, ON N6A 3K7, Canada; (S.M.); (T.J.W.); (C.R.)
- London Health Sciences Centre, London, ON N6A 5A5, Canada
| | - Theodore J. Wigle
- Department of Medicine, University of Western Ontario, London, ON N6A 3K7, Canada; (S.M.); (T.J.W.); (C.R.)
- London Health Sciences Centre, London, ON N6A 5A5, Canada
| | - Cameron Ross
- Department of Medicine, University of Western Ontario, London, ON N6A 3K7, Canada; (S.M.); (T.J.W.); (C.R.)
- London Health Sciences Centre, London, ON N6A 5A5, Canada
| | - Richard B. Kim
- Department of Medicine, University of Western Ontario, London, ON N6A 3K7, Canada; (S.M.); (T.J.W.); (C.R.)
- London Health Sciences Centre, London, ON N6A 5A5, Canada
- Lawson Health Research Institute, London, ON N6C 2R5, Canada
| |
Collapse
|
2
|
Lausten MA, Boman BM. A Review of IsomiRs in Colorectal Cancer. Noncoding RNA 2023; 9:34. [PMID: 37368334 DOI: 10.3390/ncrna9030034] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/29/2023] [Revised: 05/26/2023] [Accepted: 06/02/2023] [Indexed: 06/28/2023] Open
Abstract
As advancements in sequencing technology rapidly continue to develop, a new classification of microRNAs has occurred with the discovery of isomiRs, which are relatively common microRNAs with sequence variations compared to their established template microRNAs. This review article seeks to compile all known information about isomiRs in colorectal cancer (CRC), which has not, to our knowledge, been gathered previously to any great extent. A brief overview is given of the history of microRNAs, their implications in colon cancer, the canonical pathway of biogenesis and isomiR classification. This is followed by a comprehensive review of the literature that is available on microRNA isoforms in CRC. The information on isomiRs presented herein shows that isomiRs hold great promise for translation into new diagnostics and therapeutics in clinical medicine.
Collapse
Affiliation(s)
- Molly A Lausten
- Cawley Center for Translational Cancer Research, Helen F. Graham Cancer Center & Research Institute, Newark, DE 19713, USA
- Department of Biological Sciences, University of Delaware, Newark, DE 19713, USA
| | - Bruce M Boman
- Cawley Center for Translational Cancer Research, Helen F. Graham Cancer Center & Research Institute, Newark, DE 19713, USA
- Department of Biological Sciences, University of Delaware, Newark, DE 19713, USA
- Department of Pharmacology & Experimental Therapeutics, Thomas Jefferson University, Philadelphia, PA 19107, USA
| |
Collapse
|
3
|
Singh A, Dwivedi A. Circulating miRNA and cell-free DNA as a potential diagnostic tool in early detection of biliary tract cancer: A meta-analysis. Biomarkers 2022; 27:399-406. [PMID: 35400252 DOI: 10.1080/1354750x.2022.2064551] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Abstract
AIM To investigate the clinical efficacy of miRNA, cell-free DNA, and circulating tumor cells in biliary tract cancer diagnosis. METHODS A comprehensive literature search was conducted up to September 2021, using public databases. The quality of the screened articles was evaluated using the Quality Assessment of Diagnostic Accuracy Studies (QUADAS 2) tool followed by statistical analysis. Revman 5.4, Meta-disc 1.4, and MetaEssential were used for the statistical estimation. RESULTS A total of 28 studies were retrieved that involved 3,333 participants (1,874 patients and 1,450 control). Overall performance in terms of pooled sensitivity and specificity was 0.84 and 0.91 individually. Moreover, positive likelihood ratio (PLR), negative likelihood ratio (NLR), and area under the curve (AUC) were 10.29, 0.15, and 0.9567 respectively. Subgroup analysis based on the sample source revealed that plasma can be a prominent source in diagnosing BTC. Publication bias assessed using Begg's and Egger's test reported that no publication bias was present (p-value: 0.083, 0.162). CONCLUSIONS The miRNA and cell-free DNA exhibited a high diagnostic value in early diagnosis. While CTCs might be useful in the later stages.
Collapse
Affiliation(s)
- Aakansha Singh
- Department of Bioengineering and Biotechnology, Birla Institute of Technology, Mesra, Ranchi- 835215, Jharkhand, India
| | - Anjana Dwivedi
- Department of Bioengineering and Biotechnology, Birla Institute of Technology, Mesra, Ranchi- 835215, Jharkhand, India
| |
Collapse
|
4
|
Radanova M, Levkova M, Mihaylova G, Manev R, Maneva M, Hadgiev R, Conev N, Donev I. Single Nucleotide Polymorphisms in microRNA Genes and Colorectal Cancer Risk and Prognosis. Biomedicines 2022; 10:156. [PMID: 35052835 PMCID: PMC8773793 DOI: 10.3390/biomedicines10010156] [Citation(s) in RCA: 11] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2021] [Revised: 01/09/2022] [Accepted: 01/10/2022] [Indexed: 02/01/2023] Open
Abstract
There is growing interest in single nucleotide polymorphisms (SNPs) in the genes of microRNAs (miRNAs), which could be associated with susceptibility to colorectal cancer (CRC) and therefore for prognosis of the disease and/or treatment response. Moreover, these miRNAs-SNPs could serve as new, low-invasive biomarkers for early detection of CRC. In the present article, we performed a thorough review of different SNPs, which were investigated for a correlation with the CRC risk, prognosis, and treatment response. We also analyzed the results from different meta-analyses and the possible reasons for reported contradictory findings, especially when different research groups investigated the same SNP in a gene for a particular miRNA. This illustrates the need for more case-control studies involving participants with different ethnic backgrounds. According to our review, three miRNAs-SNPs-miR-146a rs2910164, miR-27a rs895819 and miR-608 rs4919510-appear as promising prognostic, diagnostic and predictive biomarkers for CRC, respectively.
Collapse
Affiliation(s)
- Maria Radanova
- Department of Biochemistry, Molecular Medicine and Nutrigenomics, Medical University of Varna, 9000 Varna, Bulgaria;
- Laboratory of Molecular Pathology, University Hospital “St. Marina”, 9000 Varna, Bulgaria
| | - Mariya Levkova
- Department of Medical Genetics, Medical University of Varna, 9000 Varna, Bulgaria;
| | - Galya Mihaylova
- Department of Biochemistry, Molecular Medicine and Nutrigenomics, Medical University of Varna, 9000 Varna, Bulgaria;
| | - Rostislav Manev
- Department of Oncology, Medical University of Varna, 9000 Varna, Bulgaria; (R.M.); (M.M.); (N.C.)
- Clinic of Medical Oncology, University Hospital “St. Marina”, 9000 Varna, Bulgaria
| | - Margarita Maneva
- Department of Oncology, Medical University of Varna, 9000 Varna, Bulgaria; (R.M.); (M.M.); (N.C.)
- Clinic of Medical Oncology, University Hospital “St. Marina”, 9000 Varna, Bulgaria
| | - Rossen Hadgiev
- Department of Anatomy and Histology, Pathology and Forensic Medicine, Sofia University “St. Kliment Ohridski”, 1000 Sofia, Bulgaria;
| | - Nikolay Conev
- Department of Oncology, Medical University of Varna, 9000 Varna, Bulgaria; (R.M.); (M.M.); (N.C.)
- Clinic of Medical Oncology, University Hospital “St. Marina”, 9000 Varna, Bulgaria
| | - Ivan Donev
- Clinic of Medical Oncology, Hospital “Nadezhda”, 1000 Sofia, Bulgaria;
| |
Collapse
|
5
|
Tuğrak M, Gül Hİ, Sakagami H, Kaya R, Gülçin İ. Synthesis and biological evaluation of new pyrazolebenzene-sulphonamides as potential anticancer agents and hCA I and II inhibitors. Turk J Chem 2021; 45:528-539. [PMID: 34385849 PMCID: PMC8326471 DOI: 10.3906/kim-2009-37] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2020] [Accepted: 11/12/2020] [Indexed: 12/17/2022] Open
Abstract
Cancer is a disease characterized by the continuous growth of cells without adherence to the rules that healthy normal cells obey. Carbonic anhydrase I and II (CA I and CA II) inhibitors are used for the treatment of some diseases. The available drugs in the market have limitations or side effects, which bring about the need to develop new drug candidate compound(s) to overcome the problems at issue. In this study, new pyrazole-sulphonamide hybrid compounds 4-[5-(1,3-benzodioxol-5-yl)-3-aryl-4,5-dihydro-1
H
-pyrazol-1-yl]benzenesulphonamides (4a - 4j) were designed to discover new drug candidate compounds. The compounds 4a - 4j were synthesized and their chemical structures were confirmed using spectral techniques. The hypothesis tested was whether an introduction of methoxy and polymethoxy group(s) lead to an increased potency selectivity expression (PSE) value of the compound, which reflects cytotoxicity and selectivity of the compounds. The cytotoxicity of the compounds towards tumor cell lines were in the range of 6.7 – 400 µM. The compounds 4i (PSE2 = 461.5) and 4g (PSE1 = 193.2) had the highest PSE values in cytotoxicity assays. Ki values of the compounds were in the range of 59.8 ± 3.0 - 12.7 ± 1.7 nM towards hCA I and in the range of 24.1 ± 7.1 - 6.9 ± 1.5 nM towards hCA II. While the compounds 4b, 4f, 4g, and 4i showed promising cytotoxic effects, the compounds 4c and 4g had the inhibitory potency towards hCA I and hCA II, respectively. These compounds can be considered as lead compounds for further research.
Collapse
Affiliation(s)
- Mehtap Tuğrak
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Atatürk University, Erzurum Turkey
| | - Halise İnci Gül
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Atatürk University, Erzurum Turkey
| | - Hiroshi Sakagami
- Division of Pharmacology, Meikai University School of Dentistry, Sakado, Saitama Japan
| | - Rüya Kaya
- Department of Chemistry, Faculty of Science, Atatürk University, Erzurum Turkey.,Central Research and Application Laboratory, Ağrı İbrahim Çeçen University, Ağrı Turkey
| | - İlhami Gülçin
- Department of Chemistry, Faculty of Science, Atatürk University, Erzurum Turkey
| |
Collapse
|